RTP Mobile Logo
Submitted by web@researchtop... on Mon, 04/15/2019 - 12:17

Gastric and Gastroesophageal Cancer

Track 1: Case (Dr Enzinger): A 72-year-old woman with metastatic squamous cell carcinoma of the esophagus and a high PD-L1 combined positive score (CPS) receives third-line pembrolizumab
Track 2: KEYNOTE-181: Results of a Phase III trial of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal carcinoma
Track 3: Sequencing anti-PD-1 checkpoint inhibitors for patients with metastatic HER2-negative gastric cancer and a PD-L1 CPS of 1 or higher
Track 4: Case (Dr Ilson): A 71-year-old man with microsatellite-stable gastroesophageal junction (GEJ) adenocarcinoma and a high PD-L1 CPS
Track 5: Research supporting the FDA approval of pembrolizumab for recurrent or advanced gastric or GEJ adenocarcinoma with a PD-L1 CPS of 1 or higher after 2 or more lines of chemotherapy
Track 6: Clinical implications of the negative Phase III KEYNOTE-061 trial of pembrolizumab versus paclitaxel for previously treated advanced gastric or GEJ cancer
Track 7: ATTRACTION-2: Results of a Phase III trial of nivolumab versus placebo for unresectable advanced or recurrent gastric or GEJ adenocarcinoma after at least 2 previous chemotherapy regimens
Track 8: Second-line therapy options for patients with metastatic microsatellite-stable gastric cancer who experience disease progression on first-line FOLFOX
Track 9: Results of the Phase III TAGS study: Efficacy, tolerability and potential clinical role of TAS-102 for patients with heavily pretreated metastatic gastric cancer
Track 10: INTEGRATE: Results of a Phase II trial of regorafenib for patients with refractory gastric cancer
Track 11: Select ongoing Phase III studies of other novel agents and strategies for metastatic gastric or GEJ cancer
Track 12: Approach to second-line therapy for patients with metastatic HER2-positive, microsatellite-stable gastric cancer who experience disease progression on FOLFOX/trastuzumab
Track 13: Case (Dr Enzinger): A man with moderately differentiated HER2-positive metastatic GEJ adenocarcinoma
Track 14: Case (Dr Ilson): A 67-year-old woman with proximal gastric adenocarcinoma receives neoadjuvant FOLFOX

Hepatocellular Carcinoma (HCC)

Track 15: Perspective on the recent advances in the treatment of HCC
Track 16: Selection of first-line therapy for patients with HCC
Track 17: Case (Dr Abou-Alfa): A 63-year-old man with a history of hepatitis C is diagnosed with HCC with metastasis to the bone
Track 18: Choice of lenvatinib versus sorafenib as first-line therapy
Track 19: Efficacy and tolerability of lenvatinib versus sorafenib as up-front therapy in the Phase III REFLECT trial (Study 304)
Track 20: Therapeutic options for patients with HCC in the second-line setting
Track 21: Results of the Phase III RESORCE trial of regorafenib for patients with unresectable HCC who experience disease progression on sorafenib
Track 22: Case (Dr Abou-Alfa): A 71-year-old man with Stage IV hepatitis C-related HCC requires a dose reduction with second-line cabozantinib
Track 23: Activity and side-effect profile of cabozantinib; results from the Phase III CELESTIAL trial of cabozantinib for patients with advanced HCC
Track 24: Case (Dr Greten): A 72-year-old man with a history of hepatitis B and high alpha-fetoprotein (AFP) receives ramucirumab after disease progression on sorafenib
Track 25: REACH-2: A Phase III study of ramucirumab as second-line treatment for patients with advanced HCC and elevated AFP after first-line sorafenib
Track 26: Case (Dr Greten): A 37-year-old man with HCC metastatic to the omentum achieves a pathologic complete response with durvalumab
Track 27: Role of molecular profiling for patients with HCC
Track 28: KEYNOTE-224: A Phase II study of pembrolizumab in patients with advanced HCC previously treated with sorafenib
Track 29: Activity of nivolumab in the Phase I/II CheckMate 040 study for patients with advanced HCC
Track 30: Response and tolerability of atezolizumab/bevacizumab for patients with advanced HCC on a Phase Ib trial
Track 31: Ongoing investigation of anti-PD-1/PD-L1 and anti-CTLA-4 combinations in HCC

Colorectal Cancer (CRC)

Track 32: Treatment algorithm for metastatic CRC (mCRC) based on tumor sidedness and biomarker status
Track 33: Efficacy and tolerability of anti-EGFR antibodies
Track 34: Case (Prof Van Cutsem): A 59-year old woman with mCRC, a BRAF V600E mutation and microsatellite-stable disease receives cetuximab, encorafenib and binimetinib on the BEACON CRC trial after disease progression on FOLFOX/bevacizumab
Track 35: Management of mCRC with a BRAF V600E mutation
Track 36: Results of the SWOG S1406 trial of irinotecan and cetuximab with or without vemurafenib for mCRC with a BRAF mutation
Track 37: Efficacy and safety of encorafenib, binimetinib and cetuximab in the Phase III BEACON CRC study for patients with mCRC and a BRAF V600E mutation
Track 38: Case (Dr Messersmith): A 40-year old man with microsatellite instability (MSI)-high mCRC and Lynch syndrome achieves a near-complete response after receiving an anti-PD-L1 antibody on a clinical trial
Track 39: Role of checkpoint inhibitors for patients with MSI-high mCRC
Track 40: Efficacy of anti-PD-1/PD-L1 antibodies in patients with microsatellite-stable disease
Track 41: Ongoing Phase III trials evaluating immune checkpoint inhibitors for patients with MSI-high mCRC
Track 42: Case: A 56-year-old woman with mCRC and a KRAS exon 2 mutation receives regorafenib as third-line therapy
Track 43: ReDOS: Optimal dosing of regorafenib in refractory mCRC; REVERCE: Sequencing of regorafenib and cetuximab for previously treated mCRC
Track 44: Efficacy and safety of TAS-102 in mCRC
 
FACULTY
 
Ghassan Abou-Alfa, MD
Attending
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medicine at Cornell University
New York, New York
 
Peter C Enzinger, MD
Director, Center for Esophageal and Gastric Cancer
Associate Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
 
Tim Greten, MD
Bethesda, Maryland
 
David H Ilson, MD, PhD
Professor of Medicine
Weill Cornell Medical College
Attending Physician, Memorial Hospital
Memorial Sloan Kettering Cancer Center
New York, New York
 
Wells A Messersmith, MD
Professor and Director, GI Medical Oncology Program
Co-Leader, Developmental Therapeutics Program
University of Colorado Cancer Center
Aurora, Colorado
 
Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospital Gasthuisberg/Leuven
Leuven, Belgium
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida